Birchview Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Birchview Capital’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.27M	Buy	21,032 +32	+0.2%	+$1.78K	0.59%	38
2026 Q1	$1.22M	Hold	21,000	–	–	0.7%	37
2025 Q4	$941K	Hold	21,000	–	–	0.55%	40
2025 Q3	$843K	Hold	21,000	–	–	0.64%	40
2025 Q2	$657K	Hold	21,000	–	–	0.65%	34
2025 Q1	$705K	Buy	21,000 +11,000	+110%	+$418K	0.61%	26
2024 Q4	$392K	Hold	10,000	–	–	0.32%	39
2024 Q3	$394K	Hold	10,000	–	–	0.34%	34
2024 Q2	$390K	Hold	10,000	–	–	0.36%	37
2024 Q1	$431K	Hold	10,000	–	–	0.35%	37
2023 Q4	$461K	Hold	10,000	–	–	0.36%	35
2023 Q3	$342K	Hold	10,000	–	–	0.29%	37
2023 Q2	$385K	Hold	10,000	–	–	0.29%	38
2023 Q1	$358K	Hold	10,000	–	–	0.28%	37
2022 Q4	$394K	Hold	10,000	–	–	0.28%	38
2022 Q3	$361K	Hold	10,000	–	–	0.25%	45
2022 Q2	$304K	Buy	+10,000	New	+$302K	0.22%	46

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Birchview Capital's XENE Position: Q2 2026 in Review

Birchview Capital increased its Xenon Pharmaceuticals (XENE) stake by 0.15% in Q2 2026, buying an estimated $1.78K and bringing the position to 21,032 shares worth $1.27M. The position accounts for 0.59% of the portfolio, ranked #38.

Birchview Capital first reported a position in XENE in Q2 2022 and has held it in 17 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Birchview Capital held 21,032 shares of Xenon Pharmaceuticals worth $1.27M as of Q2 2026.
Birchview Capital bought 32 Xenon Pharmaceuticals shares in Q2 2026, an estimated $1.78K.
Xenon Pharmaceuticals made up 0.59% of Birchview Capital's portfolio in Q2 2026, its #38 holding.
Birchview Capital first reported a position in Xenon Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.